Alnylam Pharmaceuticals (ALNY) Short-term Investments (2009 - 2026)

Alnylam Pharmaceuticals' Short-term Investments history runs 18 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• Quarterly Short-term Investments fell 19.12% year-over-year to $1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 billion (down 19.12% YoY) and the FY2025 annual result came in at $1.3 billion, up 15241.27% from the prior year.
• Short-term Investments was $1.3 billion for Q1 2026 at Alnylam Pharmaceuticals, up from $1.3 billion in the prior quarter.
• Across five years, Short-term Investments topped out at $1.7 billion in Q1 2022 and bottomed at $8.2 million in Q4 2024.
• A 5-year average of $702.2 million and a median of $30.9 million in 2022 frame the typical range for Short-term Investments.
• Annual changes were most pronounced in 2024 — Short-term Investments sank 99.5% — and 2025, when it jumped 15241.27%.
• Alnylam Pharmaceuticals' Short-term Investments stood at $1.3 billion in 2022, then gained by 24.47% to $1.6 billion in 2023, then sank by 99.5% to $8.2 million in 2024, then soared by 15241.27% to $1.3 billion in 2025, then rose by 3.77% to $1.3 billion in 2026.
• Business Quant data shows ALNY's Short-term Investments at $1.3 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.6 billion in Q1 2025.